SAROJA
Saroja Pharma Industries India financials
- Market cap
- ₹16 Cr
- Sector
- Chemicals
Quarterly results
Q4 FY26: revenue up 62.6%, net profit up 173.7% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 24 | 21 | 19 | 19 −29% | 35 +48% | 39 +84% | 31 +63% |
| EBITDA | 1 | 1 | 1 | 1 | 1 −11% | 2 +22% | 1 +17% | 2 +104% |
| Net profit | 1 | 1 | 1 | 0 | 0 −38% | 1 +30% | 1 +14% | 1 +174% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −19.2% 1Y
1Y: ₹49.25 on 8 Sept 2025 → ₹39.8. High ₹49.25 (8 Sept 2025), low ₹28 (30 Mar 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Reserves | ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹11 Cr | ₹12 Cr | ₹13 Cr |
| Borrowings | ₹3 Cr | ₹6 Cr | ₹10 Cr | ₹6 Cr | ₹11 Cr | ₹14 Cr |
| Other liabilities | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹10 Cr | ₹10 Cr |
| Total liabilities | ₹8 Cr | ₹16 Cr | ₹21 Cr | ₹27 Cr | ₹37 Cr | ₹42 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹6 Cr | ₹12 Cr | ₹20 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Other assets | ₹8 Cr | ₹15 Cr | ₹17 Cr | ₹18 Cr | ₹22 Cr | ₹19 Cr |
| Total assets | ₹8 Cr | ₹16 Cr | ₹21 Cr | ₹27 Cr | ₹37 Cr | ₹42 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
The ownership split has held steady since Mar 2025. The shareholder count shrank 2% to 413.
- Promoters
- 73.0%
- Public
- 27.0%
Since Mar 2025
- Promoters 0.00 pp
- Public 0.00 pp
How it drifted, 6 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 73.0%, Public 27.0%.Mar '24: Promoters 73.0%, Public 27.0%.Sep '24: Promoters 73.0%, Public 27.0%.Mar '25: Promoters 73.0%, Public 27.0%.Sep '25: Promoters 73.0%, Public 27.0%.Mar '26: Promoters 73.0%, Public 27.0%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Swastika Investmart Ltd +0.12 pp 1.99% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Saroja Pharma Industries India Ltd above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Biju Gopinathan Nair | 72.05% | unchanged |
| Swastika Investmart Ltd | 1.99% | +0.12 pp |
| Kamlesh Natwarlal Shah | 1.31% | unchanged |
| Manish Dasharath Kamble | 0.97% | unchanged |
| Rethi Krishnan Nair | 0.00% | unchanged |
| Bindu Ramachandran Kurup | 0.00% | unchanged |
| Sonal Siddarth Diwadkar | 0.00% | unchanged |
| Pulinattu Damodaran Nandakumar | 0.00% | unchanged |
| Sushama Dasharath Kamble | 0.00% | unchanged |
| Aditri Biju Nair | 0.00% | unchanged |
| Saroja Nair | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- -9.9% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Saroja Pharma Industries India Ltd
Guides on how to read this kind of business and the numbers that matter.